Scientific Foundation

We focus on how metabolic changes influence immune responses to identify high-value therapeutic entry points.

Target Mechanism

We continuously conduct mechanistic studies and validation around LDHA, seeking a deeper and clearer understanding of this target's role in disease.

Computation Empowerment

we collaborate with XtalPi (2228.HK) to leverage its FEP computation and automated synthesis platforms, enhancing the efficiency of candidate screening and optimization.

Clinical Translation

For our lead programs, we are continuously refining the integrated path from molecular design to preclinical development.
Program
Hit-to-Lead
Lead Optimisation
IND Enabling
Phase I
MP-5342
Inflammatory Bowel Disease
META-001-PH RPDDODD
Primary Hyperoxaluria
META-2
NAFLD、NASH
META-2
Hypercholesterolemia
META-3
Rheumatoid Arthritis

*For scientific and strategic considerations, we are developing two distinct lead molecules in parallel. AID: autoimmune diseases; PH: primary hyperoxaluria (rare disease).

Rare Needs Matter

Rare Needs Matter

Primary hyperoxaluria (PH) is a group of rare inherited metabolic disorders that lead to oxalate overproduction, causing recurrent kidney stones and renal damage over time. The disease typically presents in childhood or adolescence, though some patients are not diagnosed until adulthood.

In response to unmet needs, META is steadily advancing the META-001-PH program, striving to bring more possibilities and opportunities for the treatment of this disease.